Lung cancer immunophenotypic profile: a tertiary health care institute’s experience with new WHO classification
DOI:
https://doi.org/10.18203/issn.2454-2156.IntJSciRep20211454Keywords:
Lung cancer, Immunohistochemistry, WHOAbstract
Background: Lung cancer is one of the most common cancers accounting for 13% of all new cancer cases and 19% of cancer related deaths all over world. In India it constitutes 6.9% of all new cancer cases and 9.3% of all cancer related deaths in both sexes. The new 2015 WHO Classification recommends to apply immunohistochemistry, when possible, for small biopsies/cytology, and also for resected specimens.
Methods: An observational study with 113 cases between January 2017 to January 2019 received in the department of pathology. Morphological and immunohistochemical examination was done in each case.
Results: Based on morphology and immunohistochemistry cases were classified as adenocarcinoma, squamous cell carcinoma, adeno-squamous carcinoma, small cell carcinoma, and large cell carcinoma in accordance with 2015 WHO classification.
Conclusions: Classification and staging of lung cancer at the time of diagnosis is the most important predictor of survival in the era of specific targeted therapy. Immunohistochemistry is proved to be an invaluable tool for definite categorization of lung cancer cases.
Metrics
References
Malik P, Raina V. Lung cancer: Prevalent trends and emerging concepts. Indian J Med Res. 2015;141:5-7.
Hussain AN. The Lung. In: Kumar V, Abbas AK, Aster JC, eds. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Philadelphia: Saunders. 2015;712.
Carlie S, Sigel MD, Dorota E, Rudomina CT, Camelia S, Sima MD et al. Predicting adenocarcinoma outcome based on a cytology grading system. Cancer Cytopathol. 2012;120:35-43.
Kirschner B, Simonsen K, Junge J. Comparison of conventional papanicolaou smear and SurePath liquid-based cytology in the Copenhagen population screening programme for cervical cancer. Cytopathology. 2006;17:187-194.
Travis, WD, Brambilla, E, Noguchi, M. The new IASLC/ATS/ERS international multidisciplinary lung adenocarcinoma classification. J Thoracic Oncol. 2011;6:244-285.
Idowu MO, Powers CN. Lung cancer cytology: potential pitfalls and mimics - a review. Int J Clin Exp Pathol. 2010;3(4):367-85.
Travis WD, Brambilla E, Müller-Hermelink HK, Harris CC. Pathology and Genetics: Tumours of the Lung, Pleura, Thymus and Heart. IARC, Lyon. 2004.
Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature. 2012;489:519-25.
World Health Organization. Histological typing of lung tumors. World Health Organization, Geneva. 1981.
Fetsch PA, Simsir A, Brosky K, Abati A. Comparison of three commonly used cytologic preparations in effusion immunocytochemistry. Diagn Cytopathol. 2002;26:61-6.
Joseph L, Edwards JM, Nicholson CM, Pitt MA, Howat AJ. An audit of the accuracy of fine needle aspiration using a liquid-based cytology system in the setting of a rapid access breast clinic. Cytopathology. 2002;13:343-9.
Rinas AC, Mittman BW, Le LV, Hartmann K, Cayless J, Singh HK. Split-sample analysis of discarded cells from liquid-based Pap smear sampling devices. Acta Cytol. 2006;50:55-6.
Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JH, Beasley MB et al. The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification. J Thorac Oncol. 2015;10(9):1243-60.
